The Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market would witness market growth of 45.5% CAGR during the forecast period (2023-2029).
The growing awareness among patients and healthcare professionals of the potential benefits of live biotherapeutic products and microbiome-based treatments in a number of ailments, including cancer, inflammatory bowel disease (IBD), and neurological disorders.
The growing investment in LBP and microbiome-based medications by pharmaceutical and biotech companies are driving the demand for CDMOs specializing in these disciplines, and it's expected that trend will continue over the next ten years. As the demand for LBPs as well as microbiome-based therapies expands, businesses are searching for CDMOs with the expertise needed to develop and create these products.
Due to a number of factors, including the requirement for specialized facilities, tools, and operational know-how, innovative organizations have started turning to contract manufacturing for their microbiome-related research and production requirements. There are a number of advantages to outsourcing, including lower capital expenditures, quicker time-to-market, faster access to greater production capacity, and (to a major extent) better commercial risk handling as well as mitigation. Presently, a number of CMOs (contract manufacturing organizations) and CDMOs (contract development and manufacturing organizations) assert to provide services for producing items connected to the microbiome. Some in this industry have even created end-to-end capabilities, starting with drug discovery and ending with regulatory filings and commercial-scale production.
There has been a rise in the number of people diagnosed with cancer in this region. Additionally, a rise in the number of government programs to create healthcare infrastructure and the number of people who are susceptible to a variety of chronic diseases have increased the demand for novel and personalized therapies. These have been some of the primary drivers for the market in the region. Additionally, the introduction and research into the development of LBPs have the potential to have a favorable effect on the growth of markets in developed nations such as Australia, Japan, and New Zealand. It is for this reason that it is predicted that throughout the time of the forecast, these elements will present new growth chances for the players who are operating in the market.
The China market dominated the Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country in 2022, thereby, achieving a market value of $4,656 Thousands by 2029. The Japan market is anticipated to grow at a CAGR of 44.6% during (2023 - 2029). Additionally, The India market would experience a CAGR of 46.4% during (2023 - 2029).
Based on Application, the market is segmented into C.difficile, Crohns Disease, IBS, Diabetes, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Live Biotherapeutic Products And Microbiome CDMO Market is Projected to reach USD 159.1 Million by 2029, at a CAGR of 42.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB), Cerbios-Pharma SA, Biose Industrie, List Biological Laboratories, Inc., AcuraBio Pty Ltd (Ampersand Capital Partners), Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH), Quay Pharmaceuticals Ltd (SGS S.A.), BiomX, Inc., Lonza Group AG, and 4D Pharma Plc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- C.difficile
- Crohns Disease
- IBS
- Diabetes
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
- Cerbios-Pharma SA
- Biose Industrie
- List Biological Laboratories, Inc.
- AcuraBio Pty Ltd (Ampersand Capital Partners)
- Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
- Quay Pharmaceuticals Ltd (SGS S.A.)
- BiomX, Inc.
- Lonza Group AG
- 4D Pharma Plc
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, by Application
1.4.2 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
3.1 Asia Pacific C.difficile Market by Country
3.2 Asia Pacific Crohns Disease Market by Country
3.3 Asia Pacific IBS Market by Country
3.4 Asia Pacific Diabetes Market by Country
3.5 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country
4.1 China Live Biotherapeutic Products And Microbiome CDMO Market
4.1.1 China Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.2 Japan Live Biotherapeutic Products And Microbiome CDMO Market
4.2.1 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.3 India Live Biotherapeutic Products And Microbiome CDMO Market
4.3.1 India Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.4 South Korea Live Biotherapeutic Products And Microbiome CDMO Market
4.4.1 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.5 Singapore Live Biotherapeutic Products And Microbiome CDMO Market
4.5.1 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.6 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market
4.6.1 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application
4.7 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market
4.7.1 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application
Chapter 5. Company Profiles
5.1 Arranta Bio Holdings, LLC (Recipharm AB) (EQT AB)
5.1.1 Company Overview
5.1.2 Financial Analysis
5.1.3 Segmental and Regional Analysis
5.1.4 Recent strategies and developments:
5.1.4.1 Acquisition and Mergers:
5.1.4.2 Geographical Expansions:
5.2 Cerbios-Pharma SA
5.2.1 Company Overview
5.3 Biose Industrie
5.3.1 Company Overview
5.3.2 Recent strategies and developments:
5.3.2.1 Geographical Expansions:
5.4 List Biological Laboratories, Inc.
5.4.1 Company Overview
5.5 AcuraBio Pty Ltd (Ampersand Capital Partners)
5.5.1 Company Overview
5.6 Wacker Chemie AG (Dr. Alexander Wacker Familiengesellschaft mbH)
5.6.1 Company Overview
5.6.2 Financial Analysis
5.6.3 Segmental and Regional Analysis
5.6.4 Research & Development Expenses
5.7 Quay Pharmaceuticals Ltd (SGS S.A.)
5.7.1 Company Overview
5.7.2 Financial Analysis
5.7.3 Segmental Analysis
5.7.4 Recent strategies and developments:
5.7.4.1 Partnerships, Collaborations, and Agreements:
5.8 BiomX, Inc.
5.8.1 Company Overview
5.8.2 Research & Development Expenses
5.9 Lonza Group AG
5.9.1 Company Overview
5.9.2 Financial Analysis
5.9.3 Segmental and Regional Analysis
5.9.4 Research & Development Expenses
5.9.5 Recent strategies and developments:
5.9.5.1 Acquisition, Joint Ventures, and Mergers:
5.10. 4D Pharma Plc
5.10.1 Company Overview
5.10.2 Financial Analysis
5.10.3 Research & Development Expense
TABLE 1 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 2 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 4 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 5 Asia Pacific C.difficile Market by Country, 2019 - 2022, USD Thousands
TABLE 6 Asia Pacific C.difficile Market by Country, 2023 - 2029, USD Thousands
TABLE 7 Asia Pacific Crohns Disease Market by Country, 2019 - 2022, USD Thousands
TABLE 8 Asia Pacific Crohns Disease Market by Country, 2023 - 2029, USD Thousands
TABLE 9 Asia Pacific IBS Market by Country, 2019 - 2022, USD Thousands
TABLE 10 Asia Pacific IBS Market by Country, 2023 - 2029, USD Thousands
TABLE 11 Asia Pacific Diabetes Market by Country, 2019 - 2022, USD Thousands
TABLE 12 Asia Pacific Diabetes Market by Country, 2023 - 2029, USD Thousands
TABLE 13 Asia Pacific Others Market by Country, 2019 - 2022, USD Thousands
TABLE 14 Asia Pacific Others Market by Country, 2023 - 2029, USD Thousands
TABLE 15 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2022, USD Thousands
TABLE 16 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2023 - 2029, USD Thousands
TABLE 17 China Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 18 China Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 19 China Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 20 China Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 21 Japan Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 22 Japan Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 23 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 24 Japan Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 25 India Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 26 India Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 27 India Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 28 India Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 29 South Korea Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 30 South Korea Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 31 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 32 South Korea Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 33 Singapore Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 34 Singapore Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 35 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 36 Singapore Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 37 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 38 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 39 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 40 Malaysia Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 41 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2019 - 2022, USD Thousands
TABLE 42 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2023 - 2029, USD Thousands
TABLE 43 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2022, USD Thousands
TABLE 44 Rest of Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2023 - 2029, USD Thousands
TABLE 45 Key Information – Arranta Bio Holdings, LLC
TABLE 46 Key Information – Cerbios-Pharma SA
TABLE 47 Key Information – Biose Industrie
TABLE 48 Key Information – List Biological Laboratories, Inc.
TABLE 49 Key Information – AcuraBio Pty Ltd
TABLE 50 Key Information – Wacker Chemie AG
TABLE 51 Key Information – Quay Pharmaceuticals Ltd
TABLE 52 Key Information – BiomX, Inc.
TABLE 53 Key Information – Lonza Group AG
TABLE 54 Key Information – 4D Pharma Plc
List of Figures
FIG 1 Methodology for the research
FIG 2 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2022
FIG 3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market share by Application, 2029
FIG 4 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Application, 2019 - 2029, USD Thousands
FIG 5 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2022
FIG 6 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market share by Country, 2029
FIG 7 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market by Country, 2019 - 2029, USD Thousands